Skip to content

Delavirdine

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Also known as: delavirdine mesilate, delavirdine mesylate, rescriptor

OfmFDA approvedATC J05AG02

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Delavirdine is an ofm drug in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1997. Its mechanism of action is classified as Non-Nucleoside Reverse Transcriptase Inhibitors. DrugCentral lists 8 molecular targets, including pol, pol and gag-pol. Recorded indications include Human immunodeficiency virus infection.

  • Approval status: ofm (first approved 1997 by the FDA).
  • Drug class: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor.
  • Mechanism of action: Non-Nucleoside Reverse Transcriptase Inhibitors.
  • Molecular targets: pol, pol, gag-pol and reverse transcriptas (8 listed in DrugCentral).
  • Indications: Human immunodeficiency virus infection.
  • ATC code: J05AG02 (Non-nucleoside reverse transcriptase inhibitors).
  • Molecular formula: C22H28N6O3S; molecular weight 456.57 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Human immunodeficiency virus infection

Contraindications (3)

  • Achlorhydria
  • Breastfeeding (mother)
  • Disease of liver

Mechanism & targets

Mechanism of action (MoA)Non-Nucleoside Reverse Transcriptase Inhibitors
Established pharmacologic classHuman Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

Molecular targets (8)

TargetGeneActionActivity
Pol polyproteinpolunknownIC50 8.89
Reverse transcriptase/RNaseHpolinhibitorIC50 8.10
Gag-Pol polyproteingag-polunknownIC50 6.50
Reverse transcriptasereverse transcriptasunknownIC50 5.92
Histamine H4 receptorHRH4unknownKi 5.28
ATP-binding cassette sub-family G member 2ABCG2unknownIC50 4.73
Malate dehydrogenase cytoplasmic MDH1unknownIC50 4.07
Beta-lactamaseampCunknownIC50 4.05

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1997-04-04FDA—VIIV HLTHCARE

ATC classification

ATC codeTherapeutic hierarchy
J05AG02ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Non-nucleoside reverse transcriptase inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Mitochondrial toxicity643.2
Progressive external ophthalmoplegia617.0
Lipodystrophy acquired610.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Delavirdine is on its molecule page.

Molecular formulaC22H28N6O3S
Molecular weight456.57 g/mol
CAS number136817-59-9
InChIKeyWHBIGIKBNXZKFE-UHFFFAOYSA-N
PubChem CID5625
CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Delavirdine used for?

DrugCentral lists the following indications for Delavirdine: Human immunodeficiency virus infection.

How does Delavirdine work?

Delavirdine is classified as Non-Nucleoside Reverse Transcriptase Inhibitors; its molecular targets in DrugCentral include pol, pol (inhibitor), gag-pol and reverse transcriptas.

When was Delavirdine first approved?

Delavirdine was first approved by the FDA in 1997.

What drug class does Delavirdine belong to?

Delavirdine is in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class.

What is the chemical formula of Delavirdine?

Delavirdine has the molecular formula C22H28N6O3S and a molecular weight of 456.57 g/mol.

Browse: all drugs starting with D · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval1997-04-04
AgencyFDA
Targets8
Indications1
FormulaC22H28N6O3S
DrugCentral ID799
Interactive profile